The Oxandrolone hormone does not carry any estrogenic related side effects. It does not aromatize and cannot lead to gynecomastia or water retention due to increases in estrogen levels. It further carries no progestin related activity, which again supports no estrogenic related side effects. Due to water retention being impossible with this steroid, this will decrease the risk of high blood pressure. Excess water retention can promote high blood pressure. Some steroids that do not aromatize can lead to high blood pressure, such as Trenbolone , but Anavar is rarely associated with this trait.
Drugs can be added and removed from this list by WADA annually, although not all of the banned substances are explicitly named. Caroline Hatton, PhD , a sports anti-doping science consultant, told in a Mar. 12, 2010 email that "A key concept in prohibited lists is that they avoid being finite. Instead of listing all banned drugs one by one, they list entire drug classes and name drugs merely as examples. This is to keep users who took designer drugs from claiming that they didn't break the rules because the drugs they took weren't listed."
The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands .   This product was eventually discontinued and replaced in the United States with a new product named Oxandrin, which is the sole remaining brand name for oxandrolone in the United States.   Oxandrolone has also been sold under the brand names Antitriol ( Spain ), Anatrophill ( France ), Lipidex ( Brazil ), Lonavar ( Argentina , Australia , Italy ), Protivar, and Vasorome ( Japan ) among others.     Additional brand names exist for products that are manufactured for the steroid black market.